PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026ESMO Open3 citationsOpen Access

A novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study

View Full Paper
QLQ. LiuYFY. FanCHC. Huang

Key Points

  • To evaluate how different BRCA mutation locations affect responses to PARP inhibitors and prognostic outcomes in ovarian cancer.
  • Conducted a multicenter study examining BRCA mutation locations.
  • Performed comprehensive mutation profiling on epithelial ovarian cancer samples.
  • Analyzed the efficacy of PARP inhibitors based on mutation classification.
  • Identified central BRCA mutations linked to better treatment outcomes compared to N- and C-terminal mutations.
  • Demonstrated significant variation in PARP inhibitor efficacy based on mutation location.
  • Found that mutation profiling can guide treatment decisions for improved patient outcomes.

Abstract

Our novel classification revealed that PARPi efficacy and prognosis varied significantly by mutation location, with the central region linked to superior outcomes compared with the N- and C-terminal regions. Comprehensive mutation profiling should guide treatment decisions to optimize outcomes in patients with BRCA-mutated ovarian cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6980fbe1c1c9540dea80db02https://doi.org/10.1016/j.esmoop.2026.106060
Ask AI
Helpful
Bookmark
Share
View Full Paper